Hruby and Mac Hadley (University of Arizona, USA) in 19871989 Original development program Competitive Technologies Palatin Technologies , later spun off into PT-141 (bremelanotide) Target: non-selective agonist of MC1R, MC3R, MC4R, MC5R (more potent than -MSH, longer half-life) Standard experimental dose in human tanning studies: 0.025 mg/kg subcutaneously (Dorr 1996) In Dorr 1996 (n=10): increase in skin melanin density measured by colorimetry by ~25 % after a 10-day course Main adverse effects in the preclinical literature: nausea, flushing, hyperpigmentation (including atypical nevi), priapism Approximately 100+ publications in PubMed
Eur J Clin Pharmacol 1992;43:667-669
doi: 10.1039/D5FO02271A 439 FakhriRavariANguyenMHC
Fue usado fuera de prospecto - off label - para la obesidad hasta que Novo Nordisk, el laboratorio de origen dans que desarroll Ozempic, lanz un frmaco exclusivo para adelgazar
#SkinCancer #Dermatology #RadiationTherapy #IGSRT #HealthcareInnovation #PatientAccess #PhysicianLeadership #GentleCure #ChangeMedicine To view or add a comment, sign in For people living with psoriatic disease, effective care means more than improving skin
